Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.
Medicine (Baltimore)
; 100(29): e26705, 2021 Jul 23.
Article
in English
| MEDLINE | ID: covidwho-1475905
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
ABSTRACT Cytokine release syndrome (CRS) or cytokine storm is thought to be the cause of inflammatory lung damage, worsening pneumonia and death in patients with COVID-19. Steroids (Methylprednislone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for treatment of CRS in India. The aim of this study was to evaluate the efficacy and safety of combination therapy of TCZ and steroid in COVID-19 associated CRS.This retrospective cohort study was conducted at Noble hospital and Research Centre (NHRC), Pune, India between April 2 and November 2, 2020. All patients administered TCZ and steroids during this period were included. The primary endpoint was incidence of all cause mortality. Secondary outcomes studied were need for mechanical ventilation and incidence of systemic and infectious complications. Baseline and time dependent risk factors significantly associated with death were identified by Relative risk estimation.Out of 2831 admitted patients, 515 (24.3% females) were administered TCZ and steroids. There were 135 deaths (26.2%), while 380 patients (73.8%) had clinical improvement. Mechanical ventilation was required in 242 (47%) patients. Of these, 44.2% (107/242) recovered and were weaned off the ventilator. Thirty seven percent patients were managed in wards and did not need intensive care unit (ICU) admission. Infectious complications like hospital acquired pneumonia, blood stream bacterial and fungal infections were observed in 2.13%, 2.13% and 0.06% patients respectively. Age ≥ 60âyears (Pâ=â.014), presence of co-morbidities like hypertension (Pâ=â.011), IL-6 ≥ 100âpg/ml (Pâ=â.002), D-dimer ≥ 1000âng/ml (Pâ<â.0001), CT severity index ≥ 18 (Pâ<â.0001) and systemic complications like lung fibrosis (Pâ=â.019), cardiac arrhythmia (Pâ<â.0001), hypotension (Pâ<â.0001) and encephalopathy (Pâ<â.0001) were associated with increased risk of death.Combination therapy of TCZ and steroids is likely to be safe and effective in management of COVID-19 associated cytokine release syndrome. Efficacy of this anti-inflammatory combination therapy needs to be validated in randomized controlled trials.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Dexamethasone
/
Methylprednisolone
/
Antibodies, Monoclonal, Humanized
/
Cytokine Release Syndrome
/
COVID-19 Drug Treatment
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Asia
Language:
English
Journal:
Medicine (Baltimore)
Year:
2021
Document Type:
Article
Affiliation country:
MD.0000000000026705
Similar
MEDLINE
...
LILACS
LIS